INVESTIGATION ALERT: Law Firm Schall Encourages Investors in Cortexyme, Inc. with $100,000 Losses to Contact Firm – Lawyer Monthly

LOS ANGELES–(BUSINESS WIRE)–$CRTX #CRTX—Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or “the Company”) (NASDAQ : CRTX) for violating securities laws.

The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. Cortexyme issued a press release on October 26, 2021, “Report[ing] key results from its Phase 2/3 GAIN trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an orally-administered investigational small molecule that targets the bacteria’s gingipain proteases Porphyromonas gingivalis (P. gingivale). The press release said the company’s drug candidate COR388 failed to reach statistical significance in its primary endpoints, causing the company’s stock to plummet 76% the following day. In January and February 2022, the company continued to suffer setbacks, including the February 1, 2022 announcement that it would reduce its workforce by 53% as well as the resignations of Casey Lynch, CEO and Chairman of the Board of the company, and Steve Dominy. , scientific director of the Company and director.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com or by email at [email protected]

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.

Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethical requirements.

contacts

Schall law firm

Brian Schall, Esq.

310-301-3335

[email protected]
www.schallfirm.com

About Bernice Dyer

Check Also

Seven heavyweights converge on $4.5 billion Mediclinic deal

Seven leading international and South African law firms are advising on the £3.7 billion ($4.49 …